150
Participants
Start Date
February 1, 2024
Primary Completion Date
December 31, 2026
Study Completion Date
December 31, 2027
TQB2922 for injection
TQB2922 for injection is administrated to patients with advanced cancers, 28 days as a treatment cycle
NOT_YET_RECRUITING
Department of Medical Oncology, The First Hospital of China Medical University, Shenyang
NOT_YET_RECRUITING
Affiliated Zhongshan Hospital of Dalian University, Dalian
NOT_YET_RECRUITING
Harbin Medical University Cancer Hospital, Harbin
NOT_YET_RECRUITING
Shanghai Pulmonary Hospital, Shanghai
NOT_YET_RECRUITING
Nanjing Drum Tower Hospital, Nanjing
NOT_YET_RECRUITING
Tianjin Medical University Cancer Institute and Hospital, Tianjin
NOT_YET_RECRUITING
Chongqing University Cancer Hospital, Chongqing
NOT_YET_RECRUITING
The Second Xiangya Hospital of Central South University, Changsha
NOT_YET_RECRUITING
Hunan Cancer Hospital, Changsha
NOT_YET_RECRUITING
Henan Cancer Hospital, Zhengzhou
NOT_YET_RECRUITING
Henan Provincine People's Hospital, Zhengzhou
NOT_YET_RECRUITING
The First Affiliated Hospital of Zhengzhou University, Zhengzhou
RECRUITING
Sun Yat-sen University Cancer Center, Guangzhou
NOT_YET_RECRUITING
The first affiliated hospital of Guangzhou medical university, Guangzhou
NOT_YET_RECRUITING
Affiliated Hospital of North Sichuan Medical College, Nanchong
NOT_YET_RECRUITING
Yunnan Cancer Hospital, Kunming
NOT_YET_RECRUITING
The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
INDUSTRY